# **Group B Streptococcal Disease, Neonatal**

# REPORTABLE DISEASES TOOLKIT

Information for Health Care Professionals

## **Reporting Obligations**

Group B Streptococcal disease, neonatal is designated as a disease of public health significance and is reportable under the *Ontario Health Protection and Promotion Act*. Report all suspect and confirmed cases **within one business day** to the health unit.

**REPORTING FORM** 

# **Epidemiology**

#### **Aetiologic Agent:**

Group B streptococci (GBS) (S. agalactiae) are gram-positive cocci which are the most common cause of sepsis and meningitis in "at risk" newborns.

#### **Clinical Presentation:**

Two distinct forms of illness can occur:

- Early onset disease (1 7 days after birth) presents with sepsis, respiratory disease, apnea, shock, pneumonia, and meningitis.
- Late onset disease (≥ 7 days to several months after birth) presents with sepsis and meningitis, however, note that only illness up to 28 days after birth is reportable.

#### Modes of transmission:

Early onset transmission occurs via the infected birth canal as well as in utero. Late onset transmission can also be through person-to-person contact.

#### **Incubation Period:**

For early onset disease, the incubation period is from 1-7 days, presenting most frequently within the first 24 hours of life. The incubation period for late onset GBS disease in infants is unknown, as it can occur from  $\geq 7$  days to several months, but typically within 3-4 weeks.

#### **Period of Communicability:**

Group B *streptococci* are transmissible to infants during labour if the mother is colonized; however, a negative vaginal culture at the time of labour does not guarantee absence of colonization.

# **Risk Factors/Susceptibility**

- Risk is greater among premature babies; delivery at less than 37 weeks
- Intrapartum temperature greater than 38 degrees Celsius
- · Rupture of membranes for 18 hours or longer
- Having had a previous newborn with group B streptococcus infection

## **Diagnosis & Laboratory Testing**

Laboratory confirmation of Group B Streptococcus (*Streptococcus agalactiae*) from a normally sterile site (e.g., cerebrospinal fluid), with clinically compatible signs and symptoms of invasive disease in a newborn up to 28 days after birth.

Clinically compatible signs and symptoms are characterized by the following: early onset disease (1-7 days), characterized by sepsis, pneumonia, and less frequently meningitis, osteomyelitis or septic arthritis or late onset disease (7 days to 1 month), characterized by sepsis and meningitis.

**TESTING INFORMATION & REQUISITION** 

# **Treatment & Case Management**

Treatment is under the direction of the attending health care provider.

Public Health will follow up as needed.

#### **Patient Information**

PATIENT FACT SHEET

#### References

 Ministry of Health, Infectious Diseases Protocol - Ontario Public Health Standards, 2022.

#### **Additional Resources**

- SOGC. "Clinical Practice Guideline, Management of Group B Streptococcal Bacteriuria in Pregnancy, May 2012."
- 2. CDC. "Group B Strep (GBS) Prevention in Newborns, Preventing Early-Onset GBS."
- 3. PHO. "Group B Streptococcal Disease Neonatal", Dec 2022.